Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from

Jasminka Sterjovski1, Melissa J Churchill, Anne Ellett

  • 1Macfarlane Burnet Institute for Medical Research & Public Health, Melbourne, Victoria, Australia. Jasminka@burnet.edu.au

Retrovirology
|December 14, 2007
PubMed
Abstract

Insights

Enhanced fusogenicity in AIDS-causing HIV-1 variants is linked to N362, a glycosylation site near the CD4-binding site. This feature may contribute to CD4+ T-cell loss in individuals with AIDS.

Area of Science:

  • Virology
  • Immunology

Background:

  • CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) causes CD4+ T-cell loss, but pathogenicity mechanisms are unclear.
  • Understanding envelope glycoprotein (Env) determinants is crucial for R5 HIV-1 pathogenicity.

Purpose of the Study:

  • Characterize R5 Envs from asymptomatic and AIDS patients to identify determinants of pathogenicity.
  • Investigate the role of specific Env features in HIV-1 pathogenesis.

Main Methods:

  • Analyzed 37 full-length R5 Envs from pre-AIDS (PA) and AIDS (A) patients.
  • Performed quantitative cell-cell fusion assays and sequence analysis.
  • Utilized mutagenesis studies and molecular modeling.

Main Results:

  • AIDS (A)-R5 Envs exhibited enhanced fusogenicity and reduced sensitivity to T-20 compared to pre-AIDS (PA)-R5 Envs.
  • The N-linked glycosylation site N362 was more frequent in A-R5 Envs and associated with enhanced fusogenicity and faster entry kinetics.
  • N362 was linked to increased sensitivity to neutralization by the CD4-binding site (CD4bs)-directed mAb IgG1b12.

Conclusions:

  • Enhanced fusogenicity of A-R5 Envs, associated with N362, contributes to HIV-1 entry kinetics and CD4bs exposure.
  • N362 influences R5 Env fusogenicity in a strain-dependent manner.
  • Enhanced fusogenicity of A-R5 Envs, potentially mediated by N362, may contribute to CD4+ T-cell loss in AIDS progression.